Renovion Announces Addition of Rich Mattingly to Board of Directors
Updated: Sep 21, 2021
Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced the addition of Rich Mattingly to the Board of Directors. Renovion is developing ARINA-1 which is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.
C. Richard (Rich) Mattingly is highly regarded for his more than a 37-year career as a professional within the Cystic Fibrosis Foundation (CFF). Mattingly was named Executive Vice President and Chief Operating Officer of the CFF in 1993. He also served in the same capacity at its subsidiaries, Cystic Fibrosis Services, Inc. and Cystic Foundation Therapeutics Inc. and was Secretary of the Board of Trustees. He is nationally recognized for his innovative approaches to business and fundraising. The CFF is widely regarded as the most innovative non-profit of the modern era and the creators of “venture philanthropy” which led to the development of life-saving therapies. In 2015, Mattingly retired from the CFF to establish The Luv u Project, Inc. a 501(c) (3) public charity to honor his late wife, Carolyn, a passionate volunteer, philanthropist and activist. The Luv u Project mission focuses on the many challenges associated with mental health issues.
"We are so pleased to welcome Rich to our Board of Directors at this important next stage of Renovion’s evolution," stated Dr. Derek Winstanly, Renovion’s Chairman of the Board of Directors. "As a highly respected and seasoned executive with valuable respiratory experience and business acumen, we look forward to Rich’s expert engagement and assistance in guiding our objectives to bring breakthrough medicines into the hands of the patients that need them most."
"I am excited about joining the Renovion Board," stated Mr. Mattingly. "I look forward to working alongside my fellow Board members and company management to advance a truly innovative drug candidate emerging from data showing a significant benefit to patients."
Renovion is a clinical stage pharmaceutical company with a nebulized therapy that restores mucus clearance and reduces inflammation in the lungs. The company is focused on developing ARINA-1 for orphan chronic inflammatory lung diseases such as CF, Non-CF bronchiectasis and lung transplant patients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005092/en/
Dan Copeland 919 240 7034
Source: Renovion, Inc.